Last reviewed · How we verify
NCT04805710
Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI
Phase 4 trial testing clopidogrel combined with rivaroxaban arm in Rivaroxaban in 1,020 participants. Status unknown.
16 September 2022
Quick facts
| Lead sponsor | Shenyang Northern Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,020 |
| Start date | 17 March 2021 |
| Primary completion | 16 September 2022 |
| Estimated completion | 31 December 2023 |
Drugs / interventions tested
- clopidogrel combined with rivaroxaban arm — full drug profile →
Conditions studied
- Rivaroxaban — all drugs for Rivaroxaban →
Sponsor
Shenyang Northern Hospital
Who can join
Adults 18 to 75, any sex, with Rivaroxaban. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to assess the efficacy and safety of rivaroxaban or aspirin combined with clopidogrel in patients with coronary heart disease and gastrointestinal diseases undergoing PCI.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis.
Al Said S, Kaier K, Sumaya W, Alsaid D, et al · · 2024 · cited 7× · PMID 38264795 · DOI 10.1002/14651858.cd014678.pub2
Verify or expand the search:
- PubMed search for NCT04805710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rivaroxaban
Currently open trials in the same condition.
- NCT06978439 — Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease · Phase 4 · recruiting
- NCT06993636 — Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years · recruiting
Other Shenyang Northern Hospital trials
Trials by the same sponsor.
- NCT07445360 — Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary V · NA · not yet recruiting
- NCT07374718 — Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate- · NA · not yet recruiting
- NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
- NCT07362966 — Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant · Phase 4 · not yet recruiting
- NCT07383155 — Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04805710 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenyang Northern Hospital
- Last refreshed: 18 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04805710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing